Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P47 vs RoActemra PK Study in Healthy Subjects
NCT05188378Phase 1Unknown
- Sponsor
- Celltrion
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Celltrion. Primary endpoints: Area under the concentration-time curve from time zero to infinity at Day 43, Area under the concentration-time curve from time zero to the last measurable concentration at Day 43 and 1 more. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05188378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188378.